Alzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsight
The Alzheimer's disease market size is projected to grow significantly during the forecast period (2023–2032) owing to the launch of upcoming therapies and the increasing prevalence of the disease. With the launch of these therapies, many new players are expected to enter the Alzheimer's market space.
New York, USA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- *Alzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019**–2032), Assesses DelveInsight*
*The Alzheimer's disease market size is projected to grow significantly during the forecast period (2023–2032) owing to the launch of upcoming therapies and the increasing prevalence of the disease. With the launch of these therapies, many new players are expected to enter the Alzheimer's market space.*
DelveInsight’s *Alzheimer's Disease Market Insights* report includes a comprehensive understanding of current treatment practices, Alzheimer's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
*Key Takeaways from the Alzheimer's Disease Market Report*
· As per DelveInsight analysis, the Alzheimer's disease market size in the 7MM was approximately *USD 3.4 billion* in 2022.
· According to the assessment done by DelveInsight, the estimated total diagnosed prevalent Alzheimer's disease cases in the 7MM were approximately *15 million *in 2022.
· Leading Alzheimer's disease companies such as *BioVie, AB Science, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, Eli Lilly, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals, Syneos Health, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai*, and others are developing novel Alzheimer's disease drugs that can be available in the Alzheimer's disease market in the coming years.
· The promising Alzheimer's disease therapies in the pipeline include *NE3107, Masitinib (AB1010), Simufilam (PTI-125), Donanemab, Hydromethylthionine mesylate (TRx0237), Semaglutide (NN6535), KFRX01 (nilotinib BE), Remternetug (LY3372993), AR1001, Tricaprilin (CER-0001), ALZ-801 (valiltramiprosate), Piromelatine (neu-P11), Fosgonimeton (ATH-1017), Buntanetap, ANAVEX2-73 (blarcamesine), AGB101 (extended-release formulation of levetiracetam), E2814**, *and others.
Discover which therapies are expected to grab the major Alzheimer's disease market share @ *Alzheimer's Disease Market Report*
*Alzheimer's Disease Overview*
Alzheimer's disease is a progressive neurological disorder that primarily affects the memory and cognitive abilities of individuals. It is the most common form of dementia and is characterized by a gradual decline in cognitive function, eventually leading to significant impairment in daily life. While the exact cause of Alzheimer's disease is not yet fully understood, several factors are believed to contribute to its development. The exact causes of Alzheimer's disease are still being studied, but researchers believe that a combination of genetic, environmental, and lifestyle factors plays a role.
One of the key symptoms of Alzheimer's disease is memory loss, particularly recent memory loss. Individuals may struggle to remember newly learned information or important events. As the disease progresses, other symptoms such as confusion, difficulty with problem-solving and decision-making, disorientation in time and space, language problems, and changes in mood and behavior may also arise. In later stages, individuals may require assistance with basic tasks like eating, dressing, and personal hygiene. Diagnosing Alzheimer's disease can be challenging, as there is no single test that can definitively confirm its presence. Instead, doctors rely on a comprehensive evaluation that includes medical history, cognitive assessments, neurological exams, and laboratory tests to rule out other possible causes of symptoms.
*Alzheimer's Disease Epidemiology Segmentation*
DelveInsight estimates that there were approximately *15 million *diagnosed prevalent cases of Alzheimer's disease in the 7MM in 2022.
As per estimates based on DelveInsight’s epidemiology model for Alzheimer’s disease, the gender distribution of the disease suggests a female predominance across the 7MM, with approximately *5 million* male and *10 million* female cases in the 7MM in 2022.
The *Alzheimer's disease market report* proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
· Total Alzheimer's Disease Diagnosed Prevalent Cases
· Alzheimer's Disease Age-specific Cases
· Alzheimer's Disease Gender-specific Cases
· Alzheimer's Disease Severity-specific Cases
*Alzheimer's Disease Treatment Market *
Alzheimer's disease, a progressive neurodegenerative disorder, poses significant challenges for both patients and their families. While there is currently no known cure for Alzheimer's, several treatment approaches aim to manage symptoms, slow down the progression of the disease, and improve the quality of life for affected individuals. The primary focus of Alzheimer's treatment involves a combination of medications, non-pharmacological interventions, and support services. Cholinesterase inhibitors, such as *donepezil, rivastigmine, and galantamine*, are commonly prescribed to enhance neurotransmitter communication and temporarily alleviate cognitive symptoms. Another medication called *memantine *may be prescribed to help regulate glutamate activity and maintain cognitive function. Additionally, non-drug interventions like *cognitive stimulation therapy, occupational therapy, physical exercise, and social engagement* can provide significant benefits by improving memory, mood, and overall well-being. Collaborative efforts among healthcare professionals, caregivers, and support organizations play a crucial role in implementing a comprehensive treatment plan for individuals with Alzheimer's disease.
In recent years, researchers have made significant advancements in the field of Alzheimer's disease treatment, expanding the range of therapeutic options available. Targeted immunotherapies, such as *monoclonal antibodies*, have shown promise in reducing the buildup of amyloid plaques in the brain, a hallmark characteristic of Alzheimer's. These innovative treatments aim to slow down disease progression and preserve cognitive function. Another emerging area of research involves investigating the role of inflammation and oxidative stress in Alzheimer's disease. Anti-inflammatory drugs and *antioxidants *are being explored as potential treatment options to mitigate neuroinflammation and oxidative damage in the brain.
Furthermore, lifestyle modifications have gained recognition as important elements in Alzheimer's disease management. Adopting a brain-healthy diet, such as the *Mediterranean or DASH (Dietary Approaches to Stop Hypertension) diet*, can provide essential nutrients and promote cardiovascular health, which is linked to brain health. Regular physical exercise has also demonstrated positive effects in reducing the risk of cognitive decline and improving overall well-being in individuals with Alzheimer's. Additionally, maintaining social connections and participating in mentally stimulating activities, like puzzles, reading, and learning new skills, can help preserve cognitive function and enhance the quality of life.
To know more about Alzheimer's disease treatment guidelines, visit @ *Alzheimer's Disease Management** *
*Alzheimer's Disease Pipeline Therapies and Key Companies*
· NE3107: BioVie
· Masitinib (AB1010): AB Science
· Simufilam (PTI-125): Cassava Sciences
· Donanemab: Eli Lilly
· Hydromethylthionine mesylate (TRx0237): TauRx Therapeutics
· Semaglutide (NN6535): Novo Nordisk
· KFRX01 (nilotinib BE): KeifeRx
· Remternetug (LY3372993): Eli Lilly
· AR1001: AriBio
· Tricaprilin (CER-0001): Cerecin
· ALZ-801 (valiltramiprosate): Alzheon
· Piromelatine (neu-P11): Neurim Pharmaceuticals/Syneos Health
· Fosgonimeton (ATH-1017): Athira Pharma
· Buntanetap: Annovis Bio
· ANAVEX2-73 (blarcamesine): Anavex Life Sciences
· AGB101 (extended-release formulation of levetiracetam): AgeneBio
· E2814: Eisai
Learn more about the FDA-approved drugs for Alzheimer's disease @ *Drugs for* *Alzheimer's Disease Treatment** *
*Alzheimer's Disease Market Dynamics*
The Alzheimer's disease market dynamics have witnessed significant shifts in recent years. As the global population ages and life expectancy increases, the *prevalence of Alzheimer's disease* has risen, driving the demand for effective treatments and diagnostic tools. Pharmaceutical companies and biotech firms are actively investing in* research and development* to discover innovative therapies and interventions for Alzheimer's disease. Additionally, there has been a growing focus on early *detection and diagnosis*, leading to the development of advanced *imaging techniques and biomarkers*.
Furthermore, the Alzheimer's disease market is highly competitive, with multiple players striving to secure market share and gain *regulatory approvals* for their products. *Government initiatives and healthcare policies* aimed at addressing the burden of Alzheimer's disease are also influencing Alzheimer's disease market dynamics. Moreover, patient advocacy groups and organizations are playing a crucial role in *raising awareness, driving research funding*, and shaping the landscape of Alzheimer's disease care.
Alongside the market dynamics, there are several barriers that affect the Alzheimer's disease market. One of the significant challenges is the *complexity and multifactorial nature* of the disease itself. Alzheimer's disease involves intricate interactions between genetic, environmental, and lifestyle factors, making it difficult to *develop targeted interventions*. The lack of a *clear understanding* of the disease's underlying mechanisms and progression poses obstacles to the *development of effective treatments*.
Another barrier is the *high rate of failure* in clinical trials for Alzheimer's disease therapeutics. Developing new drugs for Alzheimer's is a *lengthy and costly process*, and many potential treatments have not demonstrated the desired efficacy in clinical trials. This high failure rate can discourage *investment in research and development*, leading to a scarcity of resources for innovative approaches.
Moreover, the *lack of reliable and accessible biomarkers* for early detection and accurate diagnosis is a significant barrier to Alzheimer's disease management. Early detection is crucial for implementing interventions and *evaluating treatment efficacy*, but current diagnostic methods are limited in their ability to detect the disease in its earliest stages. The *development of reliable biomarkers* that can identify individuals at risk or track disease progression could significantly impact the market dynamics.
*Report Metrics* *Details*
Study Period 2019–2032
Coverage 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]
Alzheimer's Disease Market CAGR 20%
Alzheimer's Disease Market Size in 2022 USD 3.4 Billion
Key Alzheimer's Disease Companies BioVie, AB Science, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, Eli Lilly, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals, Syneos Health, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, and others
Key Pipeline Alzheimer's Disease Therapies NE3107, Masitinib (AB1010), Simufilam (PTI-125), Donanemab, Hydromethylthionine mesylate (TRx0237), Semaglutide (NN6535), KFRX01 (nilotinib BE), Remternetug (LY3372993), AR1001, Tricaprilin (CER-0001), ALZ-801 (valiltramiprosate), Piromelatine (neu-P11), Fosgonimeton (ATH-1017), Buntanetap, ANAVEX2-73 (blarcamesine), AGB101 (extended-release formulation of levetiracetam), E2814, and others
*Scope of the **Alzheimer's Disease** Market Report*
· *Therapeutic Assessment: *Alzheimer's Disease current marketed and emerging therapies
· *Alzheimer's Disease* *Market Dynamics:* Conjoint Analysis of Emerging Alzheimer's Disease Drugs
· *Competitive Intelligence Analysis:* SWOT analysis and Market entry strategies
· *Unmet Needs, KOL’s views, Analyst’s views, Alzheimer's Disease Market Access and Reimbursement*
Discover more about Alzheimer's disease drugs in development @ *Alzheimer's Disease Clinical Trials*
*Table of Contents*
1. Alzheimer's Disease Market Key Insights
2. Alzheimer's Disease Market Report Introduction
3. Alzheimer's Disease Market Overview at a Glance
4. Alzheimer's Disease Market Executive Summary
5. Disease Background and Overview
6. Alzheimer's Disease Treatment and Management
7. Alzheimer's Disease Epidemiology and Patient Population
8. Patient Journey
9. Alzheimer's Disease Marketed Drugs
10. Alzheimer's Disease Emerging Drugs
11. 7MM Alzheimer's Disease Market Analysis
12. Alzheimer's Disease Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
*Related Reports*
*Alzheimer's Disease Epidemiology*
*Alzheimer's Disease Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted Alzheimer’s disease epidemiology in the 7MM, i.e., the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
*Alzheimer's Disease Pipeline*
*Alzheimer's Disease Pipeline Insight – 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alzheimer's Disease companies, including *Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd., Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., *among others.
*Parkinson's Disease Pipeline*
*Parkinson's Disease Pipeline Insight – 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including *Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., *among others.
*Psychosis in Parkinson’s and Alzheimer’s Disease Market*
*Psychosis in Parkinson’s and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast – 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson’s and Alzheimer’s disease companies, including *Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme,* among others.
*Neurostimulation Devices Market*
*Neurostimulation Devices** Market Insight, Competitive Landscape, and Market Forecast – 2028 *report delivers an in-depth understanding of market trends, market drivers, market barriers, and key neurostimulation devices companies, including *Medtronic PLC, Cyberonics, Boston Scientific Corporation, Abbott Laboratories,* among others.
*Deep Brain Stimulation Devices Market*
*Deep Brain Stimulation Devices **Market Insight, Competitive Landscape, and Market Forecast – 2028 *report delivers an in-depth understanding of market trends, market drivers, market barriers, and key deep brain stimulation devices companies, including *Abbott, Medtronic, Boston Scientific Corporation, ALEVA NEUROTHERAPEUTICS SA., Newronika S.p.A.,* among others.
*Other Trending Reports*
*Digestive System Fistula Market** | **Dementia With Diabetes Market** | **Leber's Hereditary Optic Neuropathy Market** | **Pecoma Market** | **Adamantinoma Market** | **Pegfilgrastim Biosimilar Insight** | **Functional Constipation Market** | **DDR Defective Tumors Market** | **Nephrotic Syndrome Pipeline** | **Pelizaeus-Merzbacher Disease Market** | **Hepatic Impairment Market** | **Primary Ciliary Dyskinesia Market** | **Surgical Bleeding Market** | Radiotherapy-Induced** Oral Mucositis Market** | **Relapsed Chronic Lymphocytic Leukemia CLL Market** | **Galactosemia Market** | **Glabellar Lines Market** | **Homozygous Familial Hypercholesterolemia Market** | **HR Positive/ HER2 Negative Breast Cancer Market** | **Lebers Hereditary Optic Neuropathy LHON Market** | **Nonalcoholic Fatty Liver Disease NAFLD Market** | **Orthotic Devices Market** | **Polypoidal Choroidal Vasculopathy Market** | **Sporadic Inclusion Body Myositis Market** | **Warm Autoimmune Hemolytic Anemia Market** | **Acid Sphingomyelinase Deficiency ASMD Market** | **B-Cell Chronic Lymphocytic Leukemia Market** | **Coccidioidomycosis Market** | **Frontotemporal Dementia Pipeline** | **Granulomatosis With Polyangiitis Market** | **Malignant Pleural Mesothelioma Market** | **Nocturnal Enuresis Market** | **Postmyocardial Infarction Syndrome Market** | **Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market** | **Typhoid Fever Market** | **Ventricular Dysfunction Market** | **Burkitt Lymphoma Market** | **Chronic Progressive Multiple Sclerosis Market** | **Emesis Market** | **Fenebrutinib Market** | **Gastric Neuroendocrine Tumors Market** | **Juvenile Rheumatoid Arthritis Market** | **Persistent Epithelial Defects Market** | **Post-Polycythemia Vera Myelofibrosis Market** | **Primary Mediastinal Large B-Cell Lymphoma Market** | **Spinocerebellar Ataxias Market** | **Systemic Inflammatory Response Syndrome Market** | **Triple Negative Breast Cancer Market** | **Visceral Pain Associated With GI Disorders Market** | **Adrenal Cortex Neoplasms Market** | **Adrenal Insufficiency Market** | **Artificial Lung Devices Market** | **Atopic Keratoconjunctivitis AKC Market** | **Autonomic Dysfunction Market** | **Bradycardia Treatment Devices Market** | **Bullous Pemphigoid Market** | **Cone Rod Dystrophy Market** | **Cutaneous Lupus Erythematosus Market** | **Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market** | **Dermal Regeneration Matrix Market** | **Heart Pump Devices Market** | **Hemiplegia Market** | **Hepatic Impairement Market** | **Immunologic Deficiency Syndrome Market** | **Implantable Infusion Pump Market** | **Menorrhalgia Market Size** | **Myocarditis Market** | **Myopia Treatment Devices Market** | **Ocular Hypertension Market** *
*Related Healthcare Services*
*Healthcare Consulting*
*Healthcare Competitive Intelligence Services*
*Healthcare Asset Prioritization Services*
*About DelveInsight*
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve*.*
*Connect with us on* *LinkedIn**|**Facebook**|**Twitter*
CONTACT: Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com